



Synjardy (empagliflozin/metformin) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI DISCLOSURE AUTHORIZATION.PDF](https://magellanrx.com/member/external/commercial/common/doc/en-us/phi-disclosure-authorization.pdf)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____

AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION		
LAST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:	
NPI NUMBER:	DEA NUMBER:	
PHONE NUMBER:	FAX NUMBER:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:	

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page.





Synjardy (empagliflozin/metformin) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? YES (if yes, complete below) NO

MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:

2. LIST DIAGNOSES: **ICD-10:**

<input type="checkbox"/> Type II diabetes <input type="checkbox"/> Type II diabetes with established cardiovascular disease <input type="checkbox"/> Type II diabetes with Congestive heart failure <input type="checkbox"/> Other Diagnosis: _____ ICD-10 Code(s): _____	
--	--

3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.

Clinical information:

For patients with Type II diabetes, please answer the following:

Is the patient's estimated glomerular filtration rate (eGFR) below 20 mL/min/1.73 m²? Yes No
Please provide documentation.

Is the patient's most recent (pre-Synjardy) HgbA1C obtained in the past 6 months 7% or greater prior to therapy (HbA1c must be taken within the past 6 months if the patient has not been on this treatment previously)? Yes No
**Please provide documentation*

Is the patient on dialysis? Yes No

For patients with Type II diabetes with established cardiovascular disease, please answer the following:

Is the patient's most recent hemoglobin A1c level within the past 6months 7.0-10%, inclusive prior to therapy (HbA1c must be taken within the past 6 months if the patient has not been on this treatment previously)? Yes No
Please provide documentation.

Does the patient's body mass index(BMI) exceed 45kg/m²? Yes No

Is the patient's estimated glomerular filtration rate (eGFR) 20 mL/min/1.73 m² or above? Yes No
Please provide documentation.

Is the patient's medical history positive for at least one of the following? Yes No
Please check at least one of the following:

- MI or Stroke
- Imaging shows single-vessel or multi-vessel coronary artery disease
- Previous coronary revascularization procedure
- Positive cardiac stress test
- Hospital admission for unstable angina
- Occulsive peripheral arterial disease (defined as limb revascularization procedure, limb or foot amputation due to circulatory insufficiency, imaging or non-invasive study showing evidence of more than 50% stenosis in an artery, and/or ankle: brachial index equaling less than 0.9 in an ankle.)





Synjardy (empagliflozin/metformin) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

For diagnosis of Type II diabetes with congestive heart failure, please answer the following:

Does patient have an ejection fraction (EF) equaling 40% or less? Yes No *Please provide documentation.*

Does patient have an ejection fraction (EF) greater than 40%? *Please provide documentation.*

Has patient ever had NYHA class II, III or IV symptoms of heart failure? Yes No *Please provide documentation.*

Does patient's body mass index (BMI) equal less than 45 kg/m²? Yes No *Please provide documentation.*

Does patient have a NT-proBNP greater than 300 pg/ml? Yes No *Please provide documentation.*

For patients with A-fib, is the NT-proBNP greater than 900 pg/ml? Yes No *Please provide documentation.*

If NT-proBNP not available, does patient have a BNP >100 pg/ml without kidney failure? Yes No
Please submit chart documentation.

If NT-proBNP not available and patient has kidney failure, does patient have a BNP > 200 pg/ml? Yes No
Please submit chart documentation.

If NT-proBNP not available and patient has Atrial fibrillation(AF), does patient have a BNP > 150 pg/ml?
 Yes No *Please submit chart documentation*

Does the patient have structural heart disease such as one or more of the following:?
Please provide documentation from echocardiogram.

- LA width >4.0cm
- LA length >5.0 cm
- LA area >20cm²
- LA volume >55ml
- LA volume index >34ml/m²

Does the patient has left ventricular hypertrophy defined by at least one of the following :?
Please provide documentation from echocardiogram.

- Septal thickness or posterior wall thickness >1.1 cm
- LV mass index(LVMI) > 115g/m² for males and > 95 g/m² for females
- E/e' (mean septal and lateral) > 13
- e' (mean septal and lateral) < 9cm/s

Has patient been hospitalized in the past 12 months before starting Synjardy(empagliflozin/metformin)?
 Yes No *Please provide documentation.*

Is patient on a stable dose of a diuretic? Yes No *Please provide documentation.*

Has patient had a myocardial infarction, coronary bypass graft surgery or other major cardiovascular surgery, stroke or TIA in the past 90 days of starting Jardiance? Yes No *Please provide documentation.*

Has patient had a heart transplant? Yes No





Synjardy (empagliflozin/metformin) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Does patient have acute decompensated heart failure? Yes No

Does patient have severe pulmonary disease including severe COPD, requiring home oxygen therapy for their COPD, chronic nebulizer therapy or chronic oral steroid therapy for treatment of their severe COPD? Yes No
Please submit chart documentation.

Does patient have severe pulmonary disease including primary pulmonary hypertension? Yes No
Please submit chart documentation.

Does patient have any other condition or diagnosis causing patient's heart failure symptoms such as patient has significant mitral valve regurgitation causing the heart failure, any dilated cardiomyopathy, infiltrative cardiomyopathy, drug induced cardiomyopathy, or viral myocarditis? Yes No
Please submit chart documentation.

Does patient have and eGFR less than 20 ml/min/1.73 m²? Yes No

Does patient require dialysis? Yes No

Is patient's heart failure related to any of the following? Yes No Please check at least one of the following:

- infiltrative disease
- accumulation disease
- muscular dystrophy
- hypertrophic obstructive cardiomyopathy
- known pericardial restriction
- valvular disease expected to lead to surgery
- atrial fib/flutter with a resting heart rate greater than 110 bpm

If prescribing for the diagnosis of chronic kidney disease(CKD), please answer the following:

Does the patient have an estimated glomerular filtration rate(eGFR) ≥20 to <45 mL/min/1.73m² ? Yes No
Please submit chart documentation.

Does the patient have an estimated glomerular filtration rate(eGFR) an eGFR ≥45 to <90 mL/min/1.73m² ? Yes No
Please submit chart documentation.

Does patient have a urinary albumin:creatinine ratio ≥200 mg/g (or protein:creatinine ratio ≥300 mg/g)? Yes No
Please submit chart documentation.

Is patient taking either a renin-angiotensin-converting enzyme inhibitor(ACEi) or or an angiotensin II receptor blocker(ARB)? Yes No *Please submit chart documentation.*

Is an ACEi or ARB contraindicated? Yes No *Please submit chart documentation.*

Does patient have TypeII diabetes AND prior atherosclerotic cardiovascular disease with an cGFR >60ml/min/1.73m² ? Yes No *Please submit chart documentation.*





Synjardy (empagliflozin/metformin) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Is patient receiving both an ACEi and an ARB at the same time? Yes No

Is patient receiving maintenance dialysis? Yes No

Has the patient received a kidney transplant? Yes No

Does patient have polycystic kidney disease? Yes No

Does patient have Type1 diabetes? Yes No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP – 4201

P.O. Box 64811

St. Paul, MN 55164-0811

